Key result
Withania somnifera constituents show strong in silico binding to cardiotoxicity targets, led by withanolide D.
Why the study?
Doxorubicin-induced cardiotoxicity is a major limitation of chemotherapy that causes irreversible cardiac damage, prompting investigation into the cardioprotective potential of Withania somnifera phytoconstituents.
In silico network pharmacology and LC-MS characterization identify withanolide D and L from Withania somnifera as candidate multi-target compounds for further preclinical testing against doxorubicin-induced cardiotoxicity.
Answers are grounded in this paper and cite their sources.
High-affinity PTGS2 binding by withanolide D supports targeted preclinical testing; leaves open any role in doxorubicin cardiotoxicity pending in vivo data.
Doxorubicin‐induced cardiotoxicity is a major limitation of chemotherapy, causing irreversible cardiac damage through oxidative stress, inflammation, and apoptosis. This study investigated the cardioprotective potential of Withania somnifera phytoconstituents using integrated in silico and analytical approaches. Phytoconstituents retrieved from the IMPPAT database were screened for drug‐likeness and ADME properties using SwissADME. Potential targets were predicted through SwissTargetPrediction and intersected with cardiotoxicity‐associated genes, followed by Gene Ontology, KEGG pathway enrichment, and network analyses. Molecular docking and molecular dynamics simulations were performed against key targets, while LC–MS analysis validated phytochemical composition. Most phytoconstituents showed favorable drug‐likeness, good gastrointestinal absorption, and minimal cytochrome P450 inhibition. Network pharmacology identified MAPK1, MAPK14, AKT1, PTGS2, and JAK2 as major targets involved in MAPK, FOXO, TNF, and VEGF signaling pathways. Molecular docking demonstrated strong binding affinities, particularly for withanolide D and withanolide L, with withanolide D showing the highest affinity toward PTGS2 (−9.7 kcal/mol). Molecular dynamics simulations confirmed stable ligand–protein interactions, while LC–MS identified major bioactive compounds including withanolide D and withanolide L. These findings suggest the cardioprotective potential of W. somnifera through multi‐target predicted pathway association and support further experimental and preclinical validation for developing plant‐based therapeutic strategies against doxorubicin‐induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Mallapur et al. (2026) studied Doxorubicin-induced cardiotoxicity. Withania somnifera phytoconstituents (including withanolide D and withanolide L) was evaluated on In silico molecular docking binding affinity against cardiotoxicity-associated targets (MAPK1, MAPK14, AKT1, PTGS2, and JAK2). Withania somnifera phytoconstituents demonstrated strong in silico binding to cardiotoxicity targets, with withanolide D showing highest affinity for PTGS2.
Synapse has enriched 10 related papers. Consider them for comparative context: